Skip to search formSkip to main contentSkip to account menu

CC-122

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Phase I/II study of avadomide (CC-122) in combination with R-CHOP for newly diagnosed DLBCL.
3501Background: In certain subsets of patients (pts) with diffuse large B-cell lymphoma (DLBCL), the failure rate of standard R… 
2019
2019
Abstract 2320: Avadomide (CC-122) increases effector function and reverses exhaustion in chronically stimulated lisocabtagene maraleucel anti-CD19 CAR T drug product
Lisocabtagene maraleucel (liso-cel) is an investigational drug product composed of autologous CD8+ and CD4+ T cells expressing a… 
2017
2017
RETRACTED ARTICLE: Thalidomide analog CC-122 induces a refractory state in monocytes from patients with diffuse large B cell lymphoma
Carolina Cubillos-Zapata, Ra ul C ordoba, Jose Avenda~ no-Ortiz and Eduardo Lopez-Collazo Tumor Immunology Laboratory, IdiPAZ… 
Review
2017
Review
2017
Recent topics in IMiDs and cereblon.
Immunomodulatory drugs (IMiDs) are a new class of anticancer compounds that are derived from thalidomide. Lenalidomide and… 
2016
2016
A Phase 1b, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-Cell Lymphoma: CC-122-DLBCL-001
Background: Relapsed/refractory (R/R) DLBCL remains an unmet medical need with no approved or standard therapy in the third-line… 
2015
2015
CC-122 Dosing on a Novel Intermittent Schedule Mitigates Neutropenia and Maintains Clinical Activity in Subjects with Relapsed or Refractory Diffuse Large B Cell Lymphoma
Background: CC-122, a first in class PPM™ pleiotropic pathway modifier, has anti-tumor activity against B cell lymphomas. The… 
2015
2015
CC-122 Exhibits Potent Anti-Lymphoma Activity in Combination with Obinutuzumab through Cell Autonomous and Antibody Dependent Cell Mediated Cytotoxicity
Background: CC-122 modulates the CRL4 E3 ligase complex, which results in recruitment and degradation of Aiolos and Ikaros. This… 
2015
2015
CC-122 Expands Activated and Memory CD4 and CD8 T Cells In Vivo and Induces T Cell Activation Ex Vivo in Subjects with Relapsed or Refractory Diffuse Large B Cell Lymphoma and Multiple Myeloma
Background: CC-122 is a first in class PPMTM pleiotropic pathway modifier compound with multiple biological activities including… 
2015
2015
Evolution: IMiDs to PPMs, revolution in DLBCL?
In this issue of Blood, Hagner et al provide preclinical evidence that CC-122 might be active in both major molecular subtypes of… 
2012
2012
CC-122 Is a Novel Pleiotropic Pathway Modifier with Potent in Vitro Immunomodulatory and Anti-Angiogenic Properties and in Vivo Anti-Tumor Activity in Hematological Cancers.
Abstract 2963 Background: The immunomodulatory agents thalidomide (THAL), lenalidomide (LEN), and pomalidomide (POM) have… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)